Envista Holdings Co. (NYSE:NVST) SVP Eric Conley Purchases 2,185 Shares of Stock

Envista Holdings Co. (NYSE:NVST) SVP Eric Conley acquired 2,185 shares of Envista stock in a transaction on Thursday, November 16th. The shares were bought at an average cost of $22.89 per share, for a total transaction of $50,014.65. Following the completion of the purchase, the senior vice president now directly owns 47,376 shares of the company’s stock, valued at $1,084,436.64. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Envista Stock Up 1.3 %

Shares of NYSE NVST opened at $23.76 on Tuesday. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.82 and a current ratio of 2.20. The firm has a market capitalization of $4.07 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 3.32 and a beta of 1.47. The stock has a 50 day moving average price of $25.24 and a 200 day moving average price of $30.59. Envista Holdings Co. has a 52-week low of $20.00 and a 52-week high of $43.29.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, November 1st. The company reported $0.43 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.46 by ($0.03). The firm had revenue of $631.30 million during the quarter, compared to analysts’ expectations of $647.94 million. Envista had a net margin of 7.39% and a return on equity of 7.29%. The firm’s revenue for the quarter was up .0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.47 EPS. Sell-side analysts expect that Envista Holdings Co. will post 1.62 earnings per share for the current year.

Institutional Trading of Envista

Hedge funds have recently bought and sold shares of the stock. Eagle Bay Advisors LLC purchased a new stake in Envista during the second quarter worth $35,000. Belpointe Asset Management LLC lifted its holdings in Envista by 80.6% during the first quarter. Belpointe Asset Management LLC now owns 901 shares of the company’s stock worth $37,000 after buying an additional 402 shares during the period. Covestor Ltd lifted its holdings in Envista by 35.0% during the first quarter. Covestor Ltd now owns 1,273 shares of the company’s stock worth $62,000 after buying an additional 330 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in Envista during the third quarter worth $47,000. Finally, Caption Management LLC purchased a new stake in shares of Envista during the 2nd quarter valued at $68,000.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on NVST. Piper Sandler cut Envista from an “overweight” rating to a “neutral” rating and reduced their price objective for the stock from $39.00 to $25.00 in a research note on Thursday, November 2nd. The Goldman Sachs Group reduced their price objective on Envista from $41.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, November 3rd. Evercore ISI cut their target price on Envista from $40.00 to $30.00 in a research note on Wednesday, October 11th. Needham & Company LLC assumed coverage on Envista in a research note on Thursday, November 16th. They set a “hold” rating on the stock. Finally, Stifel Nicolaus cut their target price on Envista from $45.00 to $36.00 and set a “buy” rating on the stock in a research note on Wednesday, November 1st. Three equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, Envista currently has an average rating of “Moderate Buy” and a consensus price target of $34.63.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists, and periodontists; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.